Brucella abortus conjugated with a peptide derived from the v3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice

Journal of Virology

Volumn 70, Issue 5, 1996, Pages 3084-3092

  Lapham, Cheryl ^a   Golding, Basil ^a   Inman, John ^b   Blackburn, Robert ^a   Manischewitz, Jody ^a   Highet, Patricia ^b   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ANTIBODY RESPONSE; ARTICLE; BRUCELLA ABORTUS; CELL STIMULATION; CONJUGATION; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; VIRUS INDUCTION; VIRUS NEUTRALIZATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; B-LYMPHOCYTES; BACTERIAL VACCINES; BRUCELLA ABORTUS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOLOGIC MEMORY; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 0029878586     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.5.3084-3092.1996     Document Type: Article

References (37)

1. Bennink, J. R., J. W. Yewdell, G. L. Smith, C. Moller, and B. Moss. 1984. Recombinant vaccima virus primes and stimulates influenza haemagglutmin-specific cytotoxic T cells. Nature (London) 311:578-579.
2. Bergmann, C., S. A. Stohlmann, and M. McMillan. 1993. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein. Eur. J. Immunol. 23:2777-2781.
3. Bloom, E. T., and J. A. Horvath. 1994. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity. J. Immunol. 152:4242-4254.
4. + T lymphocytes. Immunol. Today 9:268-274.
5. Cease, K. B., and J. A. Berzofsky. 1994. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Annu. Rev. Immunol. 12:923-989.
6. Chouaib, S., J. Chehimi, L. Bani, N. Genetet, T. Tursz, F. Gay, G. Trinchieri, and F. Mami-Chouaib. 1994. Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc. Natl. Acad. Sci. USA 91:12659-12663.
7. Ehlers, S., and K. A. Smith. 1991. Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory J. Exp. Med. 173:25-36
8. Fenyo, E. M. 1994. Antigenic variation of primate lentiviruses in humans and experimentally infected macaques. Immunol. Rev. 140:131-146
9. Golding, B., H. Golding, S. Preston, D. Hernandez, P. R. Beining, J. Manischewitz, L. Harvath, R. Blackburn, E. Lizzio, and T. Hoffman. 1991. Production of a novel antigen by conjugation of HIV-1 to Brucella abortus: studies of immunogenicity, isotype analysis. T-cell dependency and syncytia inhibition. AIDS Res. Hum. Retroviruses 7:471-482.
10. + T-cell depletion. J. Virol. 69:3299-3307
11. Goldstein, J., T. Hoffman, C. Frasch, E. F. Lizzio, P. R. Beining, D. Hochstein, Y. L. Lee, R. D. Angus, and B. Guiding. 1992. Lipopolysaccharide (LPS) from Brucella abortus is less toxic Than that from Eschenchia coli, suggesting the possible use of A abortus or LPS from B. abortus as a carrier in vaccines. Infect. Immun. 60:1386-1389
12. Harding, C. V., and R. Song. 1994 Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules J. Immunol. 153:4925-4933.
13. Ikonomidis, G., Y. Paterson, F. J. Kos, and D. A. Portnoy. 1994, Delivery of a viral antigen to the class I processing and presentation pathway by Listena monocytogenes. J. Exp. Med. 180:2209-2218.
14. Klenerman, P., S. Rowland-Jones, S. McAdam, J. Edwards. S. Daenke. D. Lalloo, B. Köppe, W. Rosenberg, D. Boyd, A. Edwards, P. Giangrande, R. E. Phillips, and A. J. McMichael. 1994. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants. Nature (London) 369:403-407.
15. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol 68:4650-4655
16. Kovacsovics-Bankowski, M., K. Clark, B. Benacerraf, and K. L. Rock. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl. Acad Sci. USA 90:4942-4946
17. Kozlowski, S., M. Corr, T. Takeshita, L. F. Boyd, C. D. Pendleton, R. N. Germain, J. A. Berzofsky, and D. H. Margulies. 1992. Serum angiotensin-I converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med. 175:1417-1422.
18. Krutzsch, H. C., and J. K. Inman. 1993. N-Isopropyliodoacetamide in the reduction and alkylation of proteins: use in microsequence analysis. Anal Biochem. 209:109-116.
19. Lewis, D. B., C. C. Yu, J. Meyer, B. K. English, S. J. Kahn, and C. B. Wilson. 1991. Cellular and molecular mechanisms for reduced interleukin 4 and interferon-γ production by neonatal T cells. J. Clin. Invest. 87:194-202.
20. - T cells suppress human immunodeficiency virus replication by inhibiting viral transcription Proc. Natl. Acad. Sci. USA 92:2308-2312.
21. + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin. Invest. 87:1462-1466.
22. McAdam, S., P. Klenerman, L. Tussey, S. Rowland-Jones, D. Lalloo, R. Phillips, A. Edwards, P. Giangrande, A. L. Brown, F. Gotch, and A. McMichael. 1995. Immunogenic HIV variant peptides that bind to HLA-BS can fail to stimulate cytotoxic T lymphocyte responses. J Immunol. 155:2729-2736.
23. McMichael, A. J., and B. D. Walker. 1994. Cytotoxic T lymphocyte epitopes: implications for HIV vaccines. AIDS 8(Suppl. 1):S155-S173.
24. Mehrotra, P. T., D. Wu, J. A. Crim, H. S. Mostowski, and J. P. Siegel. 1993. Effects of IL-12 on the generation of cytotoxic activity in human CDS- T lymphocytes. J Immunol. 151:2444-2452.
25. Mosmann, T. R., and R. L. Coffman. 1989 TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
26. Nixon, D. F., and A. J. MeMichael. 1991. Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 5:1049-1059.
27. Pfeifer, J. D., M. J. Wick, R. L. Roberts, K. Findlay, S. J. Nonmark, and C. V. Harding. 1993. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature (London) 361:359-362.
28. Sherman, L. A., T. A. Burke, and J. A. Biggs. 1992. Extracellular processing of peptide antigens that bind class I major histocompatibility molecules J Exp Med. 175:1221-1226
29. + CTL in vivo with peptide vaccine constructs J Immunol. 152:549-556
30. + T cells. Int. Immunol. 5:877-883.
31. Voss, G., and G. Hunsmann. 1993. Cellular immune response to SIVmac and HIV-2 in macaques: model for the human HIV-1 infection. J. Acquired Immune Defic. Syndr 6:969-976.
32. Walker, B. D., and F. Plata. 1990. Cytotoxic T lymphocytes against HIV AIDS 4:177-184.
33. Walker, C. M. 1993. Non-cytolytic control of HIV replication by CD8+ T cells Semin. Immunot. 5:195-201.
34. + cells involves a noncytotoxic mechanism J. Virol. 65:5921-5927.
35. White, W. I., D. R. Cassatt, J. Madsen, S. J. Burke, R. M. Woods, N. M. Wassef, C. R. Alving, and S. Koenig. 1995. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen Vaccine 13:1111-1122.
36. + T cells express Th1-like cytokme mRNA and proteins following in vitro stimulation with heat-inactivated Brucella abortus. Infect Immun 63:2720-2728.
37. Zaitseva, M. B., et al. Submitted for publication